Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer

This publication has 40 references indexed in Scilit:

• CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia
  Blood, 2008
• Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells
  BMC Cancer, 2008
• Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
  Cancer Research, 2008
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
  Nature, 2008
• The resurgence of platinum-based cancer chemotherapy
  Nature Reviews Cancer, 2007
• CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding
  British Journal of Cancer, 2006
• Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates
  Cancer Research, 2006
• The influence of HER2 genotypes as molecular markers in ovarian cancer outcome
  Biochemical and Biophysical Research Communications, 2005
• Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry
  European Journal of Cancer, 2005
• Cisplatin: mode of cytotoxic action and molecular basis of resistance
  Oncogene, 2003